Electrophysiological and antiarrhythmic actions of tocainide in isolated heart preparations of the guinea pig. 1985

U Borchard, and D Hafner, and S Ewerbeck

Comparison of the action of tocainide in guinea pig atrial and ventricular myocardium has led to the following results: Tocainide effects a similar increase in threshold of alternating current induced arrhythmias in spontaneously beating right atria as well as stimulated left atria and papillary muscles. APD30 and APD90 (action potential duration at 30 and 90% repolarization) are decreased by tocainide in papillary muscles, especially at a low stimulation rate, but increased in left atria. On the other hand, maximum upstroke velocity of the action potential (Vmax) is decreased at a high stimulation rate (use-dependence) in both tissues. These effects are completely reversed by washing with drug-free solution within 15 min in papillary muscles and 60 min in left atria, respectively. Resting state block of Na-channels by tocainide occurs in left atria to a small degree (10-20%), but is negligible in ventricular myocardium. Recovery of Vmax following stimulus-induced inactivation is delayed by tocainide in papillary muscles and left atria. Functional refractory period is increased in left atria and in papillary muscles by tocainide. In the concentration range above 75 mumol/l the concentration response curve reaches a plateau in papillary muscles but shows a further steep increase in left atria. Quantitative analysis of the dynamic Na-channel blockade by tocainide in atrial myocardium using the modulated receptor hypothesis suggests that the drug shows a high affinity to activated and a low affinity to inactivated Na-channels.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008012 Lidocaine A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE. Lignocaine,2-(Diethylamino)-N-(2,6-Dimethylphenyl)Acetamide,2-2EtN-2MePhAcN,Dalcaine,Lidocaine Carbonate,Lidocaine Carbonate (2:1),Lidocaine Hydrocarbonate,Lidocaine Hydrochloride,Lidocaine Monoacetate,Lidocaine Monohydrochloride,Lidocaine Monohydrochloride, Monohydrate,Lidocaine Sulfate (1:1),Octocaine,Xylesthesin,Xylocaine,Xylocitin,Xyloneural
D008297 Male Males
D004558 Electric Stimulation Use of electric potential or currents to elicit biological responses. Stimulation, Electric,Electrical Stimulation,Electric Stimulations,Electrical Stimulations,Stimulation, Electrical,Stimulations, Electric,Stimulations, Electrical
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D000200 Action Potentials Abrupt changes in the membrane potential that sweep along the CELL MEMBRANE of excitable cells in response to excitation stimuli. Spike Potentials,Nerve Impulses,Action Potential,Impulse, Nerve,Impulses, Nerve,Nerve Impulse,Potential, Action,Potential, Spike,Potentials, Action,Potentials, Spike,Spike Potential
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D016677 Tocainide An antiarrhythmic agent which exerts a potential- and frequency-dependent block of SODIUM CHANNELS. Tocainide Hydrochloride,Tocainide Monohdyrochloride, (R)-Isomer,Tocainide Monohydrobromide, (R)-Isomer,Tocainide Monohydrochloride,Tocainide Monohydrochloride, (+-)-Isomer,Tocainide Monohydrochloride, (S)-Isomer,Tocainide, (+-)-Isomer,Tocainide, (R)-Isomer,Tocainide, (S)-Isomer,Tonocard,W-36095,Xylotocan,Hydrochloride, Tocainide,W 36095,W36095
D066298 In Vitro Techniques Methods to study reactions or processes taking place in an artificial environment outside the living organism. In Vitro Test,In Vitro Testing,In Vitro Tests,In Vitro as Topic,In Vitro,In Vitro Technique,In Vitro Testings,Technique, In Vitro,Techniques, In Vitro,Test, In Vitro,Testing, In Vitro,Testings, In Vitro,Tests, In Vitro,Vitro Testing, In

Related Publications

U Borchard, and D Hafner, and S Ewerbeck
January 1992, Pharmacological research,
U Borchard, and D Hafner, and S Ewerbeck
June 1984, Naunyn-Schmiedeberg's archives of pharmacology,
U Borchard, and D Hafner, and S Ewerbeck
December 1990, Journal of cardiovascular pharmacology,
U Borchard, and D Hafner, and S Ewerbeck
November 1988, Naunyn-Schmiedeberg's archives of pharmacology,
U Borchard, and D Hafner, and S Ewerbeck
September 1983, British journal of pharmacology,
U Borchard, and D Hafner, and S Ewerbeck
November 1980, Naunyn-Schmiedeberg's archives of pharmacology,
U Borchard, and D Hafner, and S Ewerbeck
January 1982, Arzneimittel-Forschung,
U Borchard, and D Hafner, and S Ewerbeck
August 1983, Naunyn-Schmiedeberg's archives of pharmacology,
Copied contents to your clipboard!